Conference abstractPublished 2018
Leveraging photosynthesis via synthetic biology to address climate change and create a circular CO2-based economy with the production of cost leadership sustainable chemicals and fuels
Phytonix Corporation, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This presentation will provide an overview of how Phytonix is employing synthetic biology to address the global challenges of climate change and the production of cost competitive, sustainable chemicals and fuels. Phytonix and its organism development partners are using synthetic biology, genomics and metabolomics to develop efficient photosynthetic microbial cell factories for the direct and sustainable production of n-butanol, a valuable industrial chemical intermediate and potential “drop-in” gasoline replacement fuel, as well as other higher alcohols, from solar energy, utilizing carbon dioxide as the sole, direct feedstock with oxygen as the co-product. This is a significantly carbon-negative and sustainable process. The provision of an affordable, available and sustainable carbon source has been one of the greatest barriers to the production of economically viable renewable chemicals. Phytonix’s industrial chemical production plants, integrating its microbial cell factories along with cutting-edge process technologies, will be colocated on site at industrial facilities emitting large amounts of carbon dioxide. These include manufacturing plants, chemical plants, natural gas compression stations, coal-fired or gas-fired thermal power plants, steel mills, cement plants and even breweries. Economic and environmental opportunities and advances in industrial biotechnology with a global focus on decarbonization are leading to a rapid transition towards a new bio-economy and ultimately to a CO2-based economy for the production of consumer products. An overview of Phytonix’s current strategic partnership initiatives for scaling up to pilot production and full commercial deployment in the U.S.A. and Europe will also be discussed.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Sciences & Emerging Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Bruce Dannenberg”
